Latest Bevacizumab Stories
ResearchMoz presents this most up-to-date research on Critical Care Therapeutics in Major Developed Markets to 2020 - New and Late-Stage Four-Factor PCCs and Recombinant Products to Drive Market.
The new combination agent TAS-102 is able to improve overall survival compared to placebo in patients whose metastatic colorectal cancer is refractory to standard therapies.
For patients with KRAS wild-type untreated colorectal cancer, adding cetuximab or bevacizumab to combination chemotherapy offers equivalent survival.
LONDON, June 26, 2014 /PRNewswire/ -- Reportbuyer.com has added a new market research report:
New research report “Glioblastoma Multiforme Therapeutics in Major Developed Markets to 2019 - Growth to Hinge on the Success of Personalized Vaccine Following Early Approval in Germany” elaborated
Analysis of PRiDe, a U.S.
INDIANAPOLIS, June 11, 2014 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced that the Phase III REACH trial of CYRAMZA(TM) (ramucirumab) in patients with hepatocellular carcinoma,
INCLINE VILLAGE, Nev., June 10, 2014 /PRNewswire/ -- PDL BioPharma, Inc.
Two New Therapies Will Match Progression-Free Survival Improvements Required By Surveyed U.S.
ResearchMoz.us include new market research report "Breast Cancer Therapeutics in Major Developed Markets to 2020 - Approval of Novel Therapies to Support Continued Dominance of HER2 Targeted
- The act of burning, scorching, or heating to dryness; the state or being thus heated or dried.
- In medicine, cauterization.